Pressure BioSciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

3. Summary of Significant Accounting Policies (Details 3)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Summary Of Significant Accounting Policies Details 3
Stock options	1,605,750	1,555,500
Convertible debt		50,000
Common stock warrants	11,337,099	5,310,388
Preferred stock warrants
Series C Convertible Preferred		880,980
Series D Convertible Preferred	750,000	461,539
Series G Convertible Preferred	1,453,200
Series J Convertible Preferred	4,650,000
Total potentially dilutive shares	19,796,049	8,258,407